AbbVie’s Pediatric Kidney Disease Study Update: Implications for Investors

Abbvie (ABBV) announced an update on their ongoing clinical study.

AbbVie recently updated its clinical study titled A Phase 3, Prospective, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Paricalcitol Oral Solution for the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects Ages 0 to 9 Years With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis. The study aimed to assess the safety and effectiveness of paricalcitol in young children with severe kidney disease, highlighting its potential significance in addressing secondary hyperparathyroidism (SHPT) in this vulnerable population.

The intervention under investigation was paricalcitol, an oral solution administered to pediatric participants. This drug is intended to manage SHPT in children with stage 5 chronic kidney disease, offering a potential therapeutic option for those undergoing peritoneal or hemodialysis.

The study was designed as an interventional, single-group assignment with no masking, focusing on treatment as the primary purpose. Participants received paricalcitol three times a week over a 24-week period, divided into two 12-week dosing phases.

Key dates for this study include its initial submission on August 20, 2019, and the last update on December 2, 2025. The study was terminated, which is crucial for investors to note as it impacts the timeline and potential market release of the treatment.

The termination of this study could influence AbbVie’s stock performance, potentially affecting investor sentiment due to the halted progress in this pediatric treatment area. Competitors in the pharmaceutical industry may see this as an opportunity to advance their own research in similar therapeutic areas.

The study has been terminated, and further details are available on the ClinicalTrials portal.

To learn more about ABBV’s potential, visit the Abbvie drug pipeline page.